AstraZeneca fails in bid for early resolution of US Crestor patent litigation
This article was originally published in Scrip
Executive Summary
AstraZeneca has failed in its effort to bring an early resolution to charges of inequitable conduct which are part of the US patent litigation surrounding its blockbuster Crestor (rosuvastatin). It has not been successful in a motion for summary judgement, ahead of a February trial.